I thought some may find this interesting:
Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study
“the aim of this cohort study was to investigate effect of serum testosterone and its relationship with other laboratory parameters on the prognosis of COVID-19 in SARS-CoV-2 infected male patients.”
“hypogonadism (low testosterone) has been reported as a risk factor for diabetes, chronic obstructive pulmonary disease, metabolic syndrome, dyslipidemia, thrombotic and cardiovascular disease, leading to increased mortality in the general population [6–10]. The prevalence of hypogonadism in age hospitalized male patients has been reported as 53.3% . Low levels of testosterone have been found as an association with higher rates of infection-related hospitalization and all-cause mortality in male hemodialysis and intensive care unit patients [6,7,11,12].”
“For the first time, our data suggest that COVID-19 might deteriorate serum testosterone level in SARS-CoV-2 infected male patients. Low serum total testosterone level at baseline has a significant increased risk for the ICU and mortality in patients with COVID-19. Future studies related to testosterone treatment in this population would discover possible improvement in clinical outcomes with the testosterone treatment in SARS-CoV-2 infected hypogonadal male patients.”
While this study is not without some flaws, it would have been nice to have a control group and also a separate arm for women, those of us taking testosterone know of the health benefits of TRT and it will interesting to see what else comes out as we move forward during the pandemic.
To see the entire study: